<DOC>
	<DOCNO>NCT01121393</DOCNO>
	<brief_summary>To investigate efficacy safety BIBW 2992 compare standard first-line chemotherapy patient stage IIIB IV adenocarcinoma lung harbour EGFR activate mutation</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) vs Gemcitabine-cisplatin 1st Line Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : 1. pathologically confirm diagnosis stage IIIB stage IV adenocarcinoma Lung 2 . EGFR ( Epidermal Growth Factor Receptor ) mutation detect central laboratory analysis tumor biopsy material 3 . Measurable disease accord RECIST1.1 4 . ECOG ( Eastern Cooperative Oncology Group ) score 0 1 . 5 . Age &gt; =18 year 6. life expectancy least three month 7 . Written inform consent consistent ICHGCP guideline . Exclusion criterion : 1 . Prior chemotherapy relapse and/or metastatic NSCLC . 2 . Prior treatment EGFR target small molecule antibody . 3 . Radiotherapy surgery ( biopsy ) within 4 week prior randomization 4 . Active brain metastasis 5 . Any current malignancy malignancy diagnose within past 5 year 6 . Known preexist interstitial lung disease 7 . Significant recent acute gastrointestinal disorder diarrhoea major symptom . 8 . History presence clinically relevant cardiovascular abnormality 9 . Cardiac leave ventricular function rest ejection fraction le 50 % . 10 . Any concomitant serious illness organ system dysfunction opinion investigator would either compromise patient safety interfere evaluation safety test drug . 11 . Absolute neutrophil count ( ANC ) &lt; 1500/mm3 12 . Platelet count &lt; 100,000/mm3 13 . Creatinine clearance &lt; 60ml/min serum creatinine &gt; 1.5 time ULN ( upper limiter number ) . 14 . Bilirubin &gt; 1.5 time ULN 15 . AST ( Aspartate Amino Transferase ) ALT ( Alanine Amino Transferase ) &gt; 3 time ULN 16 . Women childbearing potential , men able father child , unwilling use medically acceptable method contraception trial 17 . Pregnancy breastfeed 18 . Patients unable comply protocol 19 . Active hepatitis B infection , active hepatitis C infection know HIV ( Human Immunodeficiency Virus ) carrier . 20 . Known suspected active drug alcohol abuse . 21. requirement treatment prohibit concomitant medication list section 4.2.2 22 . Any contraindication therapy gemcitabine/cisplatin 23 . Known hypersensitivity BIBW2992 excipient trial drug 24 . Use investigational drug within 4 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>